Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.

There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p<0.001) than patients using IDeg (n=225). Total (0.77±0.36 unit/kg/day), basal (0.43±0.20 unit/kg/day) and prandial (0.33±0.23 unit/kg/day) DIDR were similar in IGla-300 and IDeg groups. Patients with HbA1c ≤7% (n=113) used significantly lower basal (p=0.045) and total (p=0.024) DIDR, but not prandial insulin (p=0.241), than patients with HbA1c between 7.1% and 8% and >8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.

Página web DiabeTIC: estudio piloto de la satisfacción e impacto sobre el control metabólico / DiabeTIC website: a pilot study of satisfaction and impact on metabolic control

OBJECTIVOS: Evaluar la satisfacción y el impacto sobre el control metabólico a corto plazo del seguimiento de la diabetes a través de la página web DiabeTIC. MATERIAL Y MÉTODOS: Estudio prospectivo de intervención no controlado realizado en 32 pacientes de 29,7 ± 9,7 años de edad (65% mujeres) incorporados a la plataforma de telemedicina DiabeTIC entre marzo y septiembre de 2012. Todos los pacientes cumplimentaron en el primer mes un cuestionario de satisfacción, analizándose la evolución del control metabólico a los 3 y 6 meses de seguimiento. RESULTADOS: En la encuesta de satisfacción realizada en el primer mes de seguimiento se obtuvieron las siguientes puntuaciones medias (0 a 10): impresión general con la plataforma: 8,6 ± 1,8; facilidad de uso: 8,1 ± 1,5; navegación intuitiva: 6,7 ± 3,0; utilidad de las mediciones: 9,1 ± 1,1; importancia de la plataforma en el control de la diabetes: 9,5 ± 0,9; sensación de seguridad: 9,5 ± 0,8; utilidad de la biblioteca: 9,4 ± 1,1; utilidad de los mensajes: 9,1 ± 1,4, y recomendación de uso de la plataforma: 9,4 ± 0,9. Las concentraciones de hemoglobina glicosilada mejoraron significativamente a los 6 meses de seguimiento respecto al inicio del estudio (7,0 ± 0,8 versus 8,1 ± 1,9%; p = 0,007). Nueve pacientes fueron dados de baja de DiabeTIC antes de completar 6 meses de seguimiento. CONCLUSIONES: Los pacientes con diabetes seguidos a través de la página web DiabeTIC comunican un elevado grado de satisfacción, observándose a corto plazo una evolución favorable del control metabólico

OBJECTIVES: To evaluate satisfaction and short-term impact on metabolic control of diabetes monitoring through the DiabeTIC website. PATIENTS AND METHODS: A prospective, uncontrolled intervention study was conducted in 32 patients aged 29.7 ± 9.7 years (65% female) incorporated to the telemedicine platform DiabeTIC between March and September 2012. All patients completed a satisfaction questionnaire in the first month, and impact on metabolic control was evaluated at three and six months. RESULTS: In the satisfaction survey conducted in the first month of follow-up, the following mean scores (0-10) were obtained: overall impression with the platform: 8.6 ± 1.8; ease of use: 8.1 ± 1.5; intuitive navigation: 6.7 ± 3.0; value of measurements: 9.1 ± 1.1; importance of the platform in diabetes management: 9.5 ± 0.9; sense of security: 9.5 ± 0.8; value of the library: 9.4 ± 1.1; value of messages: 9.1 ± 1.4, and recommendation to use the platform: 9.4 ± 0.9. Glycosilated hemoglobin concentrations significantly improved at six months as compared to study start (7.0 ± 0.8 versus 8.1 ± 1.9; p = 0.007). Nine patients were discharged from DiabeTIC before completing six months of follow-up. CONCLUSIONS: Patients with diabetes monitored through the DiabeTIC website report a high degree of satisfaction, showing improved metabolic control at short-term follow-up

[DiabeTIC website: a pilot study of satisfaction and impact on metabolic control]. / Página web DiabeTIC: estudio piloto de la satisfacción e impacto sobre el control metabólico.

OBJECTIVES: To evaluate satisfaction and short-term impact on metabolic control of diabetes monitoring through the DiabeTIC website. PATIENTS AND METHODS: A prospective, uncontrolled intervention study was conducted in 32 patients aged 29.7±9.7 years (65% female) incorporated to the telemedicine platform DiabeTIC between March and September 2012. All patients completed a satisfaction questionnaire in the first month, and impact on metabolic control was evaluated at three and six months. RESULTS: In the satisfaction survey conducted in the first month of follow-up, the following mean scores (0-10) were obtained: overall impression with the platform: 8.6±1.8; ease of use: 8.1±1.5; intuitive navigation: 6.7±3.0; value of measurements: 9.1±1.1; importance of the platform in diabetes management: 9.5±0.9; sense of security: 9.5±0.8; value of the library: 9.4±1.1; value of messages: 9.1±1.4, and recommendation to use the platform: 9.4±0.9. Glycosilated hemoglobin concentrations significantly improved at six months as compared to study start (7.0±0.8 versus 8.1±1.9; p=0.007). Nine patients were discharged from DiabeTIC before completing six months of follow-up. CONCLUSIONS: Patients with diabetes monitored through the DiabeTIC website report a high degree of satisfaction, showing improved metabolic control at short-term follow-up.

Obesidad e hipogonadismo en paciente con diabetes tipo 2 / Obesity and hypogonadism in a patient with type 2 diabetes

No disponible

Impacto de la actividad física sobre el control metabólico y el desarrollo de complicaciones crónicas en pacientes con diabetes mellitus tipo 1 / Impact of physical activity on metabolic control and the development of chronic complications in patients with type 1 diabetes mellitus

La realización de actividad física regular constituye, junto con la dieta equilibrada, uno de los pilares básicos del tratamiento de la diabetes mellitus (DM). La práctica de actividad física en personas con DM, teóricamente, ofrece las mismas ventajas que sobre la población general, y además ciertos efectos beneficiosos, en cuanto al control metabólico de la enfermedad, como mejorar los niveles de glucemia y aumentar la acción o sensibilidad a la insulina. En la presente revisión se analizan los principales estudios clínicos publicados hasta la actualidad que evalúan el impacto de la actividad física sobre el control metabólico o el desarrollo de complicaciones crónicas en pacientes con diabetes mellitus tipo 1. A modo de conclusión podemos afirmar que la mayoría de los estudios evaluados evidencian que la práctica de actividad física regular afecta favorablemente al control metabólico de la DM (o al menos no lo empeora), existiendo insuficiente información al respecto del impacto de la actividad física sobre el desarrollo y la progresión de complicaciones crónicas (AU)

Together with a balanced diet, regular physical activity is one of the pillars of diabetes mellitus (DM) management. Physical activity theoretically provides the same advantages in people with DM as in the general population and also has some beneficial effects in controlling metabolic factors, such as improving blood glucose levels and insulin sensitivity. In this article, we analyze the main clinical studies published to date that evaluate the impact of physical activity on metabolic control or the development of chronic complications in patients with type 1 diabetes mellitus. In conclusion, most of the evaluated studies show that regular physical activity favorably affects metabolic control in DM (or at least does not have adverse effects). However, there is insufficient information about the impact of physical activity on the development and progression of chronic complications (AU)

[Impact of physical activity on metabolic control and the development of chronic complications in patients with type 1 diabetes mellitus]. / Impacto de la actividad física sobre el control metabólico y el desarrollo de complicaciones crónicas en pacientes con diabetes mellitus tipo 1.

Together with a balanced diet, regular physical activity is one of the pillars of diabetes mellitus (DM) management. Physical activity theoretically provides the same advantages in people with DM as in the general population and also has some beneficial effects in controlling metabolic factors, such as improving blood glucose levels and insulin sensitivity. In this article, we analyze the main clinical studies published to date that evaluate the impact of physical activity on metabolic control or the development of chronic complications in patients with type 1 diabetes mellitus. In conclusion, most of the evaluated studies show that regular physical activity favorably affects metabolic control in DM (or at least does not have adverse effects). However, there is insufficient information about the impact of physical activity on the development and progression of chronic complications.